| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2800235204017 | 23520401 | STELAZINE MOD.R.CA.H 2MG/CAP ΒΤx20 | 1.71 | 1.79 | 2.47 |
| 05/2018 | 2800235205014 | 23520501 | STELAZINE MOD.R.CA.H 10MG/CAP ΒΤx20 | 2.46 | 2.58 | 3.55 |
| 05/2018 | 2800235206011 | 23520601 | STELAZINE MOD.R.CA.H 15MG/CAP ΒΤx15 | 2.84 | 2.98 | 4.10 |
| 05/2018 | 2800235207018 | 23520701 | STELAZINE F.C.TAB 5MG/TAB BTx20 | 1.12 | 1.17 | 1.61 |
For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.